A Novel Study Design to Systematically Explore the Impact of Trial Methodology on Psychopharmacological Treatment Outcome in Patients with Depression

Abstract

Introduction Randomized, double-blind, placebo-controlled trials were developed to draw rather unbiased conclusions regarding the efficacy of antidepressants in the treatment of a major depressive episode (internal validity), mostly with the purpose of formal approval of new compounds in this indication. However, at the same time, data suggest that the very process of randomization and blinded administrations of placebo will have a significant impact on the efficacy of the antidepressant tested and therefore may limit the external validity of results obtained from this type of studies. Therefore, there is an urgent need to systematically study the impact of randomization/placebo control/blinding on patient population, efficacy, tolerability, and external validity in the psychopharmacological treatment of patients with a major depressive episode.

Methods To develop a study design that allows the systematic exploration of the impact of trial design on characteristics of included patient population and outcome.

Results We propose a study design including sample size calculation and statistical analysis in which patients with a major depressive episode are randomized to 3 distinct study designs that differ with regard to control, randomization, and blindness.

Discussion The results of the proposed study design may have substantial consequences when it comes to how to best interpret the results of traditional randomized, double-blind, placebo-controlled trials in the acute treatment of major depressive disorder. Furthermore, they may lead to the implementation of new study designs that may be more suitable for assessing the effectiveness of new antidepressant compounds in everyday clinical practice.

Key words

antidepressant - random allocation - trial design - randomized controlled trials as topic - major depressive disorder

• References

• 1 Perlis RH, Ostacher M, Fava M. et al. Assuring that double-blind is blind. Am J Psychiatry 2010; 167: 250-252
• 2 Otto MW, Nierenberg AA. Assay sensitivity, failed clinical trials, and the conduct of science. Psychother Psychosom 2002; 71: 241-243
• 3 Moller HJ, Maier W. Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci 2010; 260: 25-39
• 4 Moller HJ, Broich K. Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. Eur Arch Psychiatry Clin Neurosci 2010; 260: 3-16
• 5 Sinyor M, Levitt AJ, Cheung AH. et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 2010; 71: 270-279
• 6 Rutherford BR, Sneed JR, Roose SP. Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom 2009; 78: 172-181
• 7 Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19: 34-40
• 8 Papakostas GI, Ostergaard SD, Iovieno N. The nature of placebo response in clinical studies of major depressive disorder. J Clin Psychiatry 2015; 76: 456-466
• 9 Khan A, Fahl MK, Faucett J. et al. Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987–2013. World Psychiatry 2017; 16: 181-192
• 10 Nutt D, Goodwin G. ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur Neuropsychopharmacol 2011; 21: 495-499
• 11 Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013; 170: 723-733
• 12 Brody B, Leon AC, Kocsis JH. Antidepressant clinical trials and subject recruitment: just who are symptomatic volunteers?. Am J Psychiatry 2011; 168: 1245-1247
• 13 Wisniewski SR, Rush AJ, Nierenberg AA. et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009; 166: 599-607
• 14 Naudet F, Maria AS, Falissard B. Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies. PLoS One 2011; 6: e20811
• 15 Severus E, Seemuller F, Berger M. et al Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression. BMC Med 2012; 10: 67
• 16 Seemuller F, Moller HJ, Obermeier M. et al. Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials. J Clin Psychiatry 2010; 71: 1425-1433
• 17 Kelley JM, Kaptchuk TJ, Cusin C. et al. Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother Psychosom 2012; 81: 312-314
• 18 Severus E, Lipkovich I, Seemuller F. et al The potential role of marginal structural models (MSMs) in testing the effectiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice. World J Biol Psychiatry 2013; 14: 386-395
• 19 Jones R, Jones RO, McCowan C. et al. The external validity of published randomized controlled trials in primary care. BMC. Fam Pract 2009; 10: 5
• 20 Cipriani A, Furukawa TA, Salanti G. et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758
• 21 Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560
• 22 Wade A, Michael LO, Bang HK. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102
• 23 Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331-336
• 24 Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211-217